GOODYEAR, AZ – October 30th 2013 – Glen J. Weiss, MD, Director of Clinical Research, Cancer Treatment Centers of America® (CTCA) is presenting two key studies, including one today at the International Association for the Study of Lung Cancer's (IASLC) 15th World Conference on Lung Cancer being held in Sydney, Australia.
The first study, presented on October 28, involved recent results of the investigational drug, TSR-011, a potent, orally available ALK and TRK inhibitor being developed for the treatment of solid tumors including lung cancer.